Previous 10 | Next 10 |
2023-08-02 14:28:44 ET Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $106.81M (+92.1% Y/Y). Over the last 1 ...
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Goldman Sachs 44th Annual...
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the America...
2023-05-25 19:51:46 ET Summary Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schizophrenia and bipolar depression. Caplyta faces exclusivity expiration in December 2024, compelling I...
2023-05-04 13:53:06 ET Intra-Cellular Therapies, Inc. (ITCI) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Juan Sanchez – Vice President-Corporate Communications and Investor Relations Sharon Mates – Chairman and Chief Exe...
2023-05-04 07:37:59 ET Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q1 GAAP EPS of -$0.46 beats by $0.16 . Revenue of $95.31M (+172.3% Y/Y) beats by $2.9M . CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for t...
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 2023 CAPLYTA total prescriptions increa...
2023-05-03 13:39:31 ET Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.62 (+20.5% Y/Y) and the consensus Revenue Estimate is $92.41M (+164.0% Y/Y). Over t...
2023-05-01 08:33:59 ET A stronger-than expected earnings season is bolstering belief that an EPS recovery can arrive in the second half of the year, but at the same time leading macro data have slowed, according to Morgan Stanley strategist Mike Wilson. Late last week, concerns about ...
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Sc...
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Office...